The Technical AnalystExchange: NASDAQ Sector: Healthcare Industry: Biotechnology
ZIOPHARM Oncology Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.88% $0.866
America/New_York / 27 jan 2022 @ 00:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 208.12 mill |
| EPS: | -0.419 |
| P/E: | -2.07 |
| Earnings Date: | Feb 23, 2022 |
| SharesOutstanding: | 240.41 mill |
| Avg Daily Volume: | 2.36 mill |
| RATING 2022-02-09 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/20 | 3/20 | 4/20 | 1/21 | 2/21 | 3/21 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.07 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.35x |
| Company: PE -2.07 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.762 - 0.970 ( +/- 12.01%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2021-12-22 | De Groot Eleanor | Sell | 20 132 | Common Stock |
| 2021-03-04 | Thistle Mary | Buy | 150 000 | Stock Option (right to buy) |
| 2021-03-04 | Thistle Mary | Buy | 37 500 | Stock Option (right to buy) |
| 2021-03-04 | Thistle Mary | Buy | 5 000 | Common Stock |
| 2021-03-04 | Buchi J Kevin | Buy | 31 250 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 0.00 |
| Last 95 transactions |
| Buy: 4 516 054 | Sell: 1 683 458 |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.866 (-0.88% ) |
| Volume | 2.13 mill |
| Avg. Vol. | 2.36 mill |
| % of Avg. Vol | 90.04 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ZIOP
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ZIOP
ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; a patent license agreement with the National Cancer Institute; and a cooperative research and development agreement with the National Cancer Institute. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.
Latest Press Releases
Latest News
